Welcome to our dedicated page for MARSH & MCLENNAN COMPANIES SEC filings (Ticker: MRSH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on MARSH & MCLENNAN COMPANIES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into MARSH & MCLENNAN COMPANIES's regulatory disclosures and financial reporting.
MARSH & MCLENNAN COMPANIES, INC. (MRSH) director Jan Siegmund reported an acquisition of 12.03 Restricted Stock Units under the Directors Stock Compensation Plan on 2026-08-14, valued at $189.15 per unit. These RSUs were credited as dividend equivalents and are convertible into an equal number of common shares on a 1-for-1 basis.
Following this transaction, Siegmund directly holds a total of 2,310.27 Restricted Stock Units, each representing the right to receive one share of Marsh & McLennan common stock in the future.
MARSH & MCLENNAN COMPANIES, INC. (MRSH) director Steven A. Mills reported a grant of 194 shares of common stock on 2026-08-15, acquired as part of director fees under the Marsh & McLennan Companies Directors Stock Compensation Plan at a value of $188.445 per share. Following this award, Mills directly holds 5,951.75 shares and indirectly holds 47,553 shares through a trust.
MARSH & MCLENNAN COMPANIES, INC. (MRSH) reported that director Bruce D. Broussard received a grant of 192 shares of Common Stock on 2026-08-15. The award, valued at $188.445 per share, was acquired as part of director fees under the Marsh & McLennan Companies Directors Stock Compensation Plan. Following this grant, Broussard directly holds 1,617 shares of MRSH common stock.
Marsh & McLennan Companies, Inc. Chief Marketing Officer John Jude Jones reported selling 6,500 shares of common stock on 2026-08-06 in an open-market or private transaction at $191.9574 per share. After this sale, he holds 1,478 shares directly and 1,862.024 shares indirectly through the MMC 401(k) Savings & Investment Plan. These transactions were not reported as made under a Rule 10b5-1 trading plan.
MRSH has a notice of proposed sale of common stock under Rule 144. The filing lists up to 6,500 common shares to be sold through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of $1,247,723.10 as of the notice date of 08/06/2026.
The shares available for sale arise from prior restricted stock vesting awards from the issuer, including 907 shares vested on 02/28/2020, 1,324 shares on 02/28/2021, 2,258 shares on 02/28/2022, and 2,011 shares on 02/28/2023, all classified as compensation.
Paul Beswick, SVP and Chief Information Officer of Marsh & McLennan Companies, reported selling 713 shares of Common Stock on 29 July 2026 at $198 per share. The sale was executed under a previously adopted Rule 10b5-1 trading plan, leaving him with 16,376 shares of direct holdings.
Marsh & McLennan Companies’ Chief Client Officer South Martin sold 7,100 shares of Common Stock on July 28, 2026 at an average price of $189.9925 per share in an open market or private transaction.
After this sale, Martin directly owns 16,631.709 shares, including 81.17 shares acquired through the Employee Stock Purchase Plan for the quarters ended March 31 and June 30, 2026.
A holder of MRSH common stock has filed a notice to potentially sell 7,100 shares through Fidelity Brokerage Services LLC, with an aggregate value of $1,348,946.75, on or after July 28, 2026 on the NYSE. The shares relate to restricted stock awards received from the issuer as compensation, including 1,717 shares vesting on December 15, 2024 and 5,383 shares vesting on February 28, 2025.
Marsh & McLennan Companies director Lloyd M. Yates sold 12000 shares of Common Stock on July 23, 2026 at $175.6500 per share in an open-market or private transaction. After this sale, he directly owned 12000.7500 shares, and the trade was not made under a Rule 10b5-1 plan.